| Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression P Kuehl, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, PB Watkins, ... Nature genetics 27 (4), 383-391, 2001 | 2697 | 2001 |
| Genetic contribution to variable human CYP3A-mediated metabolism JK Lamba, YS Lin, EG Schuetz, KE Thummel Advanced drug delivery reviews 54 (10), 1271-1294, 2002 | 1216 | 2002 |
| Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism YS Lin, ALS Dowling, SD Quigley, FM Farin, J Zhang, J Lamba, ... Molecular pharmacology 62 (1), 162-172, 2002 | 564 | 2002 |
| Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression V Lamba, J Lamba, K Yasuda, S Strom, J Davila, ML Hancock, ... Journal of Pharmacology and Experimental Therapeutics 307 (3), 906-922, 2003 | 485 | 2003 |
| Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450 EG Schuetz, S Strom, K Yasuda, V Lecureur, M Assem, C Brimer, ... Journal of Biological Chemistry 276 (42), 39411-39418, 2001 | 453 | 2001 |
| Valproic acid pathway: pharmacokinetics and pharmacodynamics Y Ghodke-Puranik, CF Thorn, JK Lamba, JS Leeder, W Song, ... Pharmacogenetics and genomics 23 (4), 236-241, 2013 | 431 | 2013 |
| Common allelic variants of cytochrome P4503A4 and their prevalence in different populations JK Lamba, YS Lin, K Thummel, A Daly, PB Watkins, S Strom, J Zhang, ... Pharmacogenetics and Genomics 12 (2), 121-132, 2002 | 397 | 2002 |
| Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms HX Zheng, S Webber, A Zeevi, E Schuetz, J Zhang, P Bowman, G Boyle, ... American Journal of Transplantation 3 (4), 477-483, 2003 | 346 | 2003 |
| Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine CP Zamber, JK Lamba, K Yasuda, J Farnum, K Thummel, JD Schuetz, ... Pharmacogenetics and Genomics 13 (1), 19-28, 2003 | 335 | 2003 |
| Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies BC Goh, SC Lee, LZ Wang, L Fan, JY Guo, J Lamba, E Schuetz, R Lim, ... Journal of clinical oncology 20 (17), 3683-3690, 2002 | 312 | 2002 |
| PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators V Lamba, K Yasuda, JK Lamba, M Assem, J Davila, S Strom, EG Schuetz Toxicology and applied pharmacology 199 (3), 251-265, 2004 | 259 | 2004 |
| The emerging role of electronic medical records in pharmacogenomics RA Wilke, H Xu, JC Denny, DM Roden, RM Krauss, CA McCarty, ... Clinical Pharmacology & Therapeutics 89 (3), 379-386, 2011 | 204 | 2011 |
| Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study PL Anderson, J Lamba, CL Aquilante, E Schuetz, CV Fletcher JAIDS Journal of Acquired Immune Deficiency Syndromes 42 (4), 441-449, 2006 | 200 | 2006 |
| PharmGKB summary: very important pharmacogene information for CYP3A5 J Lamba, JM Hebert, EG Schuetz, TE Klein, RB Altman Pharmacogenetics and genomics 22 (7), 555-558, 2012 | 197 | 2012 |
| Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism HX Zheng, A Zeevi, E Schuetz, J Lamba, K McCurry, BP Griffith, S Webber, ... The Journal of Clinical Pharmacology 44 (2), 135-140, 2004 | 196 | 2004 |
| CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults RC Givens, YS Lin, ALS Dowling, KE Thummel, JK Lamba, EG Schuetz, ... Journal of Applied Physiology 95 (3), 1297-1300, 2003 | 186 | 2003 |
| Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression J Lamba, V Lamba, S Strom, R Venkataramanan, E Schuetz Drug metabolism and disposition 36 (1), 169-181, 2008 | 167 | 2008 |
| Genetic factors influencing cytarabine therapy JK Lamba Pharmacogenomics 10 (10), 1657-1674, 2009 | 165 | 2009 |
| Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics J Lamba, V Lamba, E Schuetz Current drug metabolism 6 (4), 369-383, 2005 | 163 | 2005 |
| CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children’s Oncology Group trial AAML0531 JK Lamba, L Chauhan, M Shin, MR Loken, JA Pollard, YC Wang, RE Ries, ... Journal of Clinical Oncology 35 (23), 2674, 2017 | 147 | 2017 |
Erin SchuetzSt Jude Children's Research HospitalZweryfikowany adres z stjude.org
